Results 1 to 10 of about 27,325 (117)

Impact of myopia and myopia control interventions on binocular vision: A narrative review [PDF]

Indian Journal of Ophthalmology
Myopia is the fastest-growing, chronic eye condition that covers 30% of the population worldwide and is estimated to be around 50% of the global population (5 billion people) by 2050.
Shobha Gupta, Nayan Gupta
doaj   +2 more sources

The Evolution of Myopia Control Spectacle Lenses in Türkiye [PDF]

Türk Oftalmoloji Dergisi
Uğur Emrah Altıparmak
doaj   +2 more sources

Eye Care Practitioners Are Key Influencer for the Use of Myopia Control Intervention

Frontiers in Public Health, 2022
BackgroundThe study sought to investigate the self-reported practices of Singaporean eye care practitioners on myopia management and the interaction between eye care practitioners and parents.MethodsSelf-reported questionnaire (1) to eye care ...
Adeline Yang, Bao Y. Pang, Pushpaja Vasudevan, Björn Drobe   +3 more
doaj   +1 more source

Long-term results of orthokeratology correction combined with 0.01 % atropine instilliations in children and adolescents with progressive myopia of various degrees

Российский офтальмологический журнал, 2023
Purpose. To evaluate the effectiveness of control of myopia of various degrees in children and adolescents with the combined use of orthokeratology (OK) correction and ultralow-dose atropine instillations (0.01 %) over a long-term follow-up period (up to
T. Yu. Verzhanskaya
doaj   +1 more source

Multiple Factors Causing Myopia and the Possible Treatments: A Mini Review

Frontiers in Public Health, 2022
The myopia epidemic has become a global public health problem. Although myopia is progressing worldwide, the recent coronavirus infections 2019 (COVID-19) outbreak has spurred myopia progression.
Ari Shinojima, Ari Shinojima, Kazuno Negishi, Kazuo Tsubota, Toshihide Kurihara, Toshihide Kurihara   +5 more
doaj   +1 more source

Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression

Scientific Reports, 2023
To evaluate the age-related efficacy and safety of atropine 0.01% eye drops over 2 years for myopia control in a multicentric pediatric Spanish cohort. A non-controlled, interventional, prospective multicenter study was conducted as an extension of the ...
Inés Pérez-Flores, Beatriz Macías-Murelaga, Multicenter Group of Atropine Treatment for Myopia Control (GTAM), Jesús Barrio-Barrio   +3 more
doaj   +1 more source

Global Tendency and Frontiers of Research on Myopia From 1900 to 2020: A Bibliometrics Analysis

Frontiers in Public Health, 2022
Background:Myopia is one of the most common causes of vision impairment in children and adults and has become a public health priority with its growing prevalence worldwide. This study aims to identify and evaluate the global trends in myopia research of
Mengyuan Shan, Yi Dong, Yi Dong, Jingyi Chen, Qing Su, Yan Wang, Yan Wang, Yan Wang   +7 more
doaj   +1 more source

Role of 7-methylxanthine in myopia prevention and control: a mini-review [PDF]

International Journal of Ophthalmology, 2023
Myopia is becoming increasingly common. By 2050 around 10% of the world's population is expected to be highly myopic (
Lu Lai, Klaus Trier, Dong-Mei Cui
doaj   +1 more source

A multicenter Spanish study of atropine 0.01% in childhood myopia progression

Scientific Reports, 2021
To evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed.
Inés Pérez-Flores, Beatríz Macías-Murelaga, Jesús Barrio-Barrio, Multicenter Group of Atropine Treatment for Myopia Control (GTAM)   +3 more
doaj   +1 more source

Research progress on genetic patterns and prevention and control measures for high myopia

Zhongguo linchuang yanjiu, 2023
High myopia is a highly population-specific and genetically heterogeneous eye disease for which there is no effective treatment. Myopia is more prevalent and severe in east Asians, especially in China.
TENG Fengwu, LI Yadi, XU Xinyue, XUE Liping   +3 more
doaj   +1 more source